- Baseline clinical data of the 3 studied groups (N=199).
| Baseline clinical data | Total | DVS (n=75) | NB (n=64) | VBS (n=60) | P-value |
|---|---|---|---|---|---|
| n (%) | |||||
| Initial eGFR mL/min/1.73 m2 | |||||
| Median (range) | 39.61 (135.4) | 45.15 (134.3) | 66.2 (134.3) | 23.1 (106.3) | |
| Min (max) | 3.2 (138.6) | 3.6 (129.7) | 4.3 (138.6) | 3.2 (109.5) | 0.001 |
| Mean±SD | 50.1±2.77 | 49.8±36.9 | 66.2±44.04 | 33.1±27.9 | |
| Last follow-up eGFR mL/min/1.73 m2 | |||||
| Median (range) | 59.97 (137.3) | 55.0 (136.0) | 90.8 (136.7) | 37.7 (135.6) | |
| Min (max) | 3.1 (140.4) | 4.2 (140.2) | 3.7 (140.4) | 3.1 (138.7) | 0.000 |
| Mean±SD | 66.4±3.3 | 65.1±46.1 | 84.9±46.1 | 48.2±40.6 | |
| Comparison median initial eGFR: last eGFR, p-value | <0.001 | <0.001 | 0.002 | 0.021 | |
| Hydronephrosis | |||||
| Negative | 38 (19.1) | 8 (10.7) | 21 (32.8) | 9 (15.0) | |
| Positive | 161 (80.9) | 67 (89.3) | 43 (67.2) | 51 (85) | 0.002 |
| Unilateral | 49 (30.4) | 14 (20.9) | 22 (51.2) | 13 (25.5) | |
| Bilateral | 112 (69.6) | 53 (79.1) | 21 (48.8) | 38 (74.5) | |
| VUR | |||||
| Negative | 105 (52.8) | 34 (45.2) | 46 (71.9) | 25 (41.7) | |
| Positive | 94 (47.2) | 41 (54.7) | 18 (28.1) | 35 (58.3) | 0.618 |
| Unilateral | 79 (84.0) | 33 (80.5) | 15 (83.3) | 31 (88.6) | |
| Bilateral | 15 (16.0) | 8 (19.5) | 3 (16.7) | 4 (11.4) | |
| Scars on DMSA | |||||
| Negative | 37 (38.1) | 18 (47.4) | 11 (28.9) | 8 (38.1) | |
| Positive | 60 (61.9) | 20 (52.6) | 27 (71.1) | 13 (61.9) | 0.657 |
| Unilateral renal scars | 34 (56.7) | 10 (50.0) | 17 (63.0) | 7 (53.8) | |
| Bilateral renal scars | 26 (43.3) | 10 (50.0) | 10 (37.0) | 6 (46.2) | |
| Obstruction on DTPA/MAG3, n=144 | 65 (45.1) | 20 (35.1) | 22 (48.9) | 23 (54.8) | 0.125 |
| CIC | 113 (56.8) | 40 (53.3) | 46 (71.9) | 27 (45.0) | |
| Oxybutynin | 123 (61.8) | 48 (64.0) | 48 (75.0) | 27 (45.0) | |
| Comorbidity | |||||
| Pyelonephritis | 102 (37.2) | 44 (58.7) | 33 (51.6) | 25 (41.7) | 0.145 |
| Hypertension | 42 (15.3) | 24 (32.0) | 10 (15.6) | 8 (13.3) | 0.013 |
| Proteinuria | 24 (8.8) | 13 (17.3) | 1 (1.6) | 10 (16.7) | 0.007 |
| Hematuria | 5 (1.9) | 5 (6.7) | 0 (0) | 0 (0) | 0.012 |
| Progressive CKD | 61 (22.2) | 22 (29.3) | 17 (26.6) | 22 (36.7) | 0.452 |
| End Stage CKD | 40 (14.6) | 14 (18.7) | 9 (14.1) | 17 (28.3) | 0.132 |
| RRT | 23 (11.5) | 11 (14.6) | 4 (6.25) | 8 (13.3) | |
| Non | 176 (88.4) | 64 (85.3) | 61 (95.3) | 52 (86.7) | |
| Hemodialysis | 11 (5.5) | 6 (8.0) | 1 (1.6) | 4 (6.7) | |
| Peritoneal | 11 (5.5) | 5 (6.7) | 1 (1.6) | 4 (6.7) | |
| Transplantation | 1 (0.5) | 0 (0.0) | 1 (1.6) | 0 (0.0) | |
| Mortality | |||||
| Mortality secondary to ESKD | 8 (4.02) | 4 (5.3) | 4 (6.2) | 0 (0.0) | |
Proteinuria ≥300 mg/L. Hematuria >10 HPF. Hypertension >95th percentile for age, gender, and height; CKD, worsening eGFR <60 ml/min/1.73 m2; end stage kidney disease, eGFR <15 ml/min/1.73 m2. DVS: dysfunction voiding syndrome, NB: neurogenic bladder due to spinal dysraphisim, VBS: valve bladder syndrome, SD: standard deviation, Max: maximum, eGFR: estimated glomerular filtration rate, RRT: renal replacement therapy, VUR: vesico-ureteral reflux, DMSA: di-mercapto-succinic acid, DTPA: diethylenetriamine penta-acetic acid, MAG3: technetium 99 mercapto-acetyl-triglycine scan, CIC: clean intermittent catheterization, CKD: chronic kidney disease